Management of Hypercalcemia in Suspected Multiple Myeloma

Severe Hypercalcemia (Serum Calcium > 14 mg/dL)

• Initiate aggressive intravenous hydration combined with an intravenous bisphosphonate (zoledronic acid or pamidronate) or denosumab; add calcitonin for the first 48–72 hours to rapidly lower calcium levels. Evidence: clinical recommendations from the Endocrine Society (2023) based on randomized trials and expert consensus. [1][2]

Moderate Hypercalcemia (Serum Calcium 12–14 mg/dL)

• Begin intravenous hydration together with an intravenous bisphosphonate or denosumab to achieve calcium reduction; no routine use of calcitonin is required. Evidence: Endocrine Society guidance (2023) derived from moderate‑quality clinical studies. [1][2]

Renal Considerations (Patients with Chronic Kidney Disease)

• Prefer denosumab over bisphosphonates for treating severe hypercalcemia when renal impairment is present, because bisphosphonates require dose adjustment and may exacerbate kidney injury. Evidence: Endocrine Society recommendation (2023) reflecting pharmacokinetic data and safety analyses in CKD populations. 2

Hypercalcemia at Serum Calcium 12.6 mg/dL: Clinical Manifestations and Malignancy Definition

Clinical Manifestations

• Adults with a serum calcium of approximately 12.6 mg/dL commonly experience constitutional symptoms such as fatigue, constipation, nausea, vomiting, increased urine output, gastrointestinal upset, and progressive dehydration. 3

Definition of Malignancy‑Associated Hypercalcemia (Multiple Myeloma)

• In the context of multiple myeloma, hypercalcemia of malignancy is defined as a corrected serum calcium level exceeding 11.5 mg/dL (≈2.65 mmol/L) that is attributable to the plasma‑cell proliferative disorder and is frequently accompanied by bone disease and heightened bone resorption. [4][3]